GlaxoSmithKline and Genmab A/S Announce Start of Ofatumumab Phase III Combination Study in Non-Hodgkin’s Lymphoma

LONDON and COPENHAGEN, Denmark, Sept. 8, 2010 (GLOBE NEWSWIRE) -- Summary: GSK and Genmab announce the initiation of a Phase III study of ofatumumab in rituximab refractory patients with indolent B-cell non-Hodgkin's Lymphoma.